AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34758875 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 35544650 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies at community-based partner sites
Number of subjects: 84
Study 35544650 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigator-initiated randomized therapeutic radiation trials in the MSK Alliance
Number of subjects: 84
Study 35544650 — intervention group
Group type: COMPARATOR
Intervention: Matched trials open only at the main academic center
Number of subjects: 84
Study 33267864 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra marital affairs of partners
Number of subjects: 538
Study 33267864 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption by partners
Number of subjects: 538
Study 33267864 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent drawing water
Number of subjects: 538
Study 33267864 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of IPV
Number of subjects: 538
Study 35611849 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary Spiritist Therapy (CST)
Number of subjects: 76
Study 35611849 — intervention group
Group type: COMPARATOR
Intervention: Control (routine maintenance)
Number of subjects: 76
Study 35611849 — intervention group
Group type: EXPERIMENTAL
Intervention: CST
Number of subjects: 76
Study 35611849 — intervention group
Group type: EXPERIMENTAL
Intervention: CST (≥7 sessions)
Number of subjects: 76
Study 35611849 — intervention group
Group type: EXPERIMENTAL
Intervention: CST (2-3 sessions per week)
Number of subjects: 76
Study 33419400 — intervention group
Group type: EXPERIMENTAL
Intervention: LA (lidocaine cream smeared to the cuff of the LMA before insertion, with mask removal in the awake state)
Number of subjects: 392
Study 33419400 — intervention group
Group type: COMPARATOR
Intervention: LD (lidocaine application and LMA removal under deep anesthesia)
Number of subjects: 392
Study 33419400 — intervention group
Group type: COMPARATOR
Intervention: NLA (hydrosoluble lubricant application and LMA removal in the awake state)
Number of subjects: 392
Study 33419400 — intervention group
Group type: COMPARATOR
Intervention: NLD (hydrosoluble lubricant application and LMA removal in deep anesthesia)
Number of subjects: 392
Study 33419400 — intervention group
Group type: EXPERIMENTAL
Intervention: LA
Number of subjects: 392
Study 33419400 — intervention group
Group type: COMPARATOR
Intervention: LD
Number of subjects: 392
Study 33419400 — intervention group
Group type: COMPARATOR
Intervention: NLA
Number of subjects: 392
Study 33419400 — intervention group
Group type: COMPARATOR
Intervention: NLD
Number of subjects: 392
Study 33419400 — intervention group
Group type: EXPERIMENTAL
Intervention: LA and NLA
Number of subjects: 392
Study 32372458 — intervention group
Group type: EXPERIMENTAL
Intervention: Creams with nanoliposomes encapsulated with skimmed donkey milk
Number of subjects: 15
Study 32372458 — intervention group
Group type: EXPERIMENTAL
Intervention: Night cream with nanoliposomes encapsulated with skimmed donkey milk
Number of subjects: 15
Study 32372458 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 15
Study 32372458 — intervention group
Group type: COMPARATOR
Intervention: Untreated skin
Number of subjects: 15
Study 32372458 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (Creams with donkey milk, Placebo cream, Untreated skin)
Number of subjects: 15
Study 34787952 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g of d‐β‐hydroxybutyrate (βHB) in the form of a KE drink (ΔG®)
Number of subjects: 10
Study 34787952 — intervention group
Group type: COMPARATOR
Intervention: 25 g of d‐β‐hydroxybutyrate (βHB) in the form of a KE drink (ΔG®) with 2 g of L‐alanine
Number of subjects: 10
Study 32798283 — intervention group
Group type: EXPERIMENTAL
Intervention: RSLV‐132 (10 mg/kg)
Number of subjects: 30
Study 32798283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 32674241 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-based recommendations (FBR)
Number of subjects: 102
Study 32674241 — intervention group
Group type: COMPARATOR
Intervention: Non-Food-based recommendations (non-FBR)
Number of subjects: 102
Study 33219136 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic BP target of 110 to 139 mm Hg)
Number of subjects: 1000
Study 33219136 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (systolic BP target of 140 to 179 mm Hg)
Number of subjects: 1000
Study 33219136 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 1000
Study 33219136 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 1000
Study 32705121 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-session stress management intervention (n = 60)
Number of subjects: 120
Study 32705121 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 60)
Number of subjects: 120
Study 34637055 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser in addition to mechanical therapy (n=16)
Number of subjects: 50
Study 34637055 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser in addition to mechanical therapy (n=17)
Number of subjects: 50
Study 34637055 — intervention group
Group type: COMPARATOR
Intervention: Conventional non-surgical mechanical therapy (Control group, n=17)
Number of subjects: 50
Study 35323853 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH intervention
Number of subjects: 88
Study 35323853 — intervention group
Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 88
Study 34897211 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical metronidazole ointment
Number of subjects: 120
Study 34897211 — intervention group
Group type: COMPARATOR
Intervention: Oral metronidazole
Number of subjects: 120
Study 34897211 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 120
Study 33667827 — intervention group
Group type: EXPERIMENTAL
Intervention: Living Through Psychosis (LTP) group programme
Number of subjects: 55
Study 32496865 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of community resources
Number of subjects: 950
Study 32496865 — intervention group
Group type: EXPERIMENTAL
Intervention: Lethal risk factors
Number of subjects: 950
Study 32496865 — intervention group
Group type: EXPERIMENTAL
Intervention: In-law encouragement of IPV
Number of subjects: 950
Study 32496865 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive norms around community resource utilisation
Number of subjects: 950
Study 34993754 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Connects (FC)
Number of subjects: 994
Study 34993754 — intervention group
Group type: COMPARATOR
Intervention: Natural comparison group (control)
Number of subjects: 994
Study 32897570 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprocitentan 10 mg/day for 9 days
Number of subjects: 28
Study 32897570 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprocitentan 25 mg/day for 9 days
Number of subjects: 28
Study 32897570 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprocitentan 50 mg/day for 9 days
Number of subjects: 28
Study 32897570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 35639602 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-003
Number of subjects: 14627
Study 35639602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14627
Study 33630387 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Number of subjects: 158
Study 33630387 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg
Number of subjects: 158
Study 33630387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 33402627 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetized water
Number of subjects: 20
Study 33402627 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine
Number of subjects: 20
Study 34569335 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 week of plaster cast
Number of subjects: 40
Study 34569335 — intervention group
Group type: COMPARATOR
Intervention: 4 to 5 weeks of plaster cast
Number of subjects: 40
Study 36137949 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Hz rTMS treatment of the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 46
Study 36137949 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 46
Study 33789429 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder external rotation strength training program (2 exercises, 3 times per week for 8 weeks)
Number of subjects: 92
Study 33789429 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 92
Study 32525715 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome-adaptive randomization
Number of subjects: 0
Study 34387891 — intervention group
Group type: EXPERIMENTAL
Intervention: United States written rules for environmental risk regulation
Number of subjects: 45
Study 34387891 — intervention group
Group type: COMPARATOR
Intervention: China's written rules for environmental risk regulation
Number of subjects: 45
Study 35081915 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative method (elevating the arm to 90° for 10 seconds after 6 mg of adenosine)
Number of subjects: 30
Study 35081915 — intervention group
Group type: COMPARATOR
Intervention: Standard method (double syringe technique of 6 mg of adenosine)
Number of subjects: 30
Study 35081915 — intervention group
Group type: COMPARATOR
Intervention: Both groups (alternative and standard methods)
Number of subjects: 30
Study 34153022 — intervention group
Group type: EXPERIMENTAL
Intervention: NPWT with TCDO instillation (NPWTi)
Number of subjects: 48
Study 34153022 — intervention group
Group type: COMPARATOR
Intervention: Standard NPWT
Number of subjects: 48
Study 32814313 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD‐10 codes for cirrhosis diagnosis
Number of subjects: 3396
Study 34418302 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorbable glass microfiber matrix (Mirragen; Advanced Wound Matrix [BBGFM])
Number of subjects: 40
Study 34418302 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC, collagen alginate dressing)
Number of subjects: 40
Study 32861369 — intervention group
Group type: EXPERIMENTAL
Intervention: Goniometer-Pro android app
Number of subjects: 71
Study 32861369 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-rater reliability
Number of subjects: 71
Study 32861369 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-rater reliability
Number of subjects: 71
Study 36161276 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincisional intravenous paracetamol
Number of subjects: 0
Study 36161276 — intervention group
Group type: COMPARATOR
Intervention: Postincisional intravenous paracetamol
Number of subjects: 0
Study 36161276 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 33847022 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunnel technique with subepithelial connective tissue graft (TUN+CTG)
Number of subjects: 18
Study 33847022 — intervention group
Group type: COMPARATOR
Intervention: Coronally advanced flap with enamel matrix derivate (CAF+EMD)
Number of subjects: 18
Study 33020101 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive oscillating device (NIOD) at 40 Hz
Number of subjects: 60
Study 33020101 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive oscillating device (NIOD) at 60 Hz
Number of subjects: 60
Study 33020101 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive oscillating device (NIOD)
Number of subjects: 60
Study 33020101 — intervention group
Group type: COMPARATOR
Intervention: Chest physiotherapy (CPT)
Number of subjects: 60
Study 33020101 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive oscillating device (NIOD) and CPT
Number of subjects: 60
Study 34785763 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigil immunotherapy
Number of subjects: 0
Study 34785763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35690181 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 50 mg
Number of subjects: 20
Study 35690181 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 250 mg
Number of subjects: 20
Study 35690181 — intervention group
Group type: COMPARATOR
Intervention: d9-caffeine (molar-equivalent dose)
Number of subjects: 20
Study 32580698 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-wedge trial with unequal cluster sizes
Number of subjects: 0
Study 32580698 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment‐vs‐time period correlation
Number of subjects: 0
Study 32580698 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute treatment group imbalance
Number of subjects: 0
Study 32580698 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 0
Study 32580698 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization algorithm
Number of subjects: 0
Study 36447198 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis session with self-hypnosis posthypnotic suggestions
Number of subjects: 169
Study 36447198 — intervention group
Group type: COMPARATOR
Intervention: Conversational interview with the hypnotherapist (Control)
Number of subjects: 169
Study 33663659 — intervention group
Group type: COMPARATOR
Intervention: Saline + 5 mg tropisetron (Group A)
Number of subjects: 485
Study 33663659 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg methylprednisolone sodium succinate + 5 mg tropisetron (Group B)
Number of subjects: 485
Study 35616597 — intervention group
Group type: COMPARATOR
Intervention: Modified osoto-gari defence reaction
Number of subjects: 26
Study 35616597 — intervention group
Group type: EXPERIMENTAL
Intervention: Common osoto-gari defence reaction
Number of subjects: 26
Study 35896895 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer-coated everolimus-eluting stents (BP-EES)
Number of subjects: 120
Study 35896895 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer-coated everolimus-eluting stents (DP-EES)
Number of subjects: 120
Study 34076230 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25(OH)D) levels in DVT group
Number of subjects: 280
Study 34076230 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25(OH)D) levels in females of DVT group
Number of subjects: 280
Study 34076230 — intervention group
Group type: COMPARATOR
Intervention: Serum 25-hydroxyvitamin D (25(OH)D) levels in control group
Number of subjects: 280
Study 34076230 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis of 25(OH)D
Number of subjects: 280
Study 34076230 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight, height, and body mass index
Number of subjects: 280
Study 33539582 — intervention group
Group type: EXPERIMENTAL
Intervention: Active network-tDCS
Number of subjects: 38
Study 33539582 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 38
Study 33539582 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38
Study 32363608 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaningful and Enjoyable Activities Scale (MEAS)
Number of subjects: 63
Study 32363608 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional independence
Number of subjects: 63
Study 32363608 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised three-factor 9-item model
Number of subjects: 63
Study 36160382 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel alone
Number of subjects: 40
Study 36160382 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel + ilaprazole
Number of subjects: 40
Study 36383391 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3
Number of subjects: 535
Study 36383391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 535
Study 32305093 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib with obinutuzumab
Number of subjects: 535
Study 32305093 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib monotherapy
Number of subjects: 535
Study 32305093 — intervention group
Group type: COMPARATOR
Intervention: Obinutuzumab-chlorambucil
Number of subjects: 535
Study 616026493 — intervention group
Group type: EXPERIMENTAL
Intervention: BBFC + PGA (Brinzolamide 1%/Brimonidine 0.2%)
Number of subjects: 182
Study 616026493 — intervention group
Group type: COMPARATOR
Intervention: Vehicle + PGA
Number of subjects: 182
Study 616026493 — intervention group
Group type: EXPERIMENTAL
Intervention: BBFC + TRAVATAN Z
Number of subjects: 182
Study 616026493 — intervention group
Group type: COMPARATOR
Intervention: Vehicle + TRAVATAN Z
Number of subjects: 182
Study 616026493 — intervention group
Group type: EXPERIMENTAL
Intervention: BBFC + XALATAN
Number of subjects: 182
Study 616026493 — intervention group
Group type: COMPARATOR
Intervention: Vehicle + XALATAN
Number of subjects: 182
Study 616026493 — intervention group
Group type: EXPERIMENTAL
Intervention: BBFC + LUMIGAN
Number of subjects: 182
Study 616026493 — intervention group
Group type: COMPARATOR
Intervention: Vehicle + LUMIGAN
Number of subjects: 182
Study 35413923 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA intensity for 20 min)
Number of subjects: 64
Study 35413923 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 64
Study 35413923 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 64
Study 34619933 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist's assessment of bleeding risk and targeted medication education using warfarin medication checklist at discharge
Number of subjects: 147
Study 34619933 — intervention group
Group type: COMPARATOR
Intervention: Routine warfarin medication education at discharge
Number of subjects: 147
Study 34619933 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin medication checklist
Number of subjects: 147
Study 32807252 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WP) supplementation, 20 g twice a day for 15 days
Number of subjects: 0
Study 32807252 — intervention group
Group type: COMPARATOR
Intervention: Casein (CA) supplementation, 20 g twice a day for 15 days
Number of subjects: 0
Study 35330408 — intervention group
Group type: EXPERIMENTAL
Intervention: PENG block
Number of subjects: 58
Study 35330408 — intervention group
Group type: COMPARATOR
Intervention: FICB
Number of subjects: 58
Study 33577995 — intervention group
Group type: EXPERIMENTAL
Intervention: n-back task (3-back)
Number of subjects: 38
Study 33577995 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-back task
Number of subjects: 38
Study 33577995 — intervention group
Group type: EXPERIMENTAL
Intervention: n-back task (2-back)
Number of subjects: 38
Study 33577995 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-back and n-back tasks
Number of subjects: 38
Study 32293967 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal function exercises (VFEs) + vocal hygiene
Number of subjects: 40
Study 32293967 — intervention group
Group type: COMPARATOR
Intervention: Vocal hygiene only
Number of subjects: 40
Study 36509982 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (AT) intervention group (MS-AT)
Number of subjects: 61
Study 36509982 — intervention group
Group type: COMPARATOR
Intervention: Motor training control group (MS-C)
Number of subjects: 61
Study 33200245 — intervention group
Group type: EXPERIMENTAL
Intervention: ACB combined with LFCNB
Number of subjects: 160
Study 33200245 — intervention group
Group type: COMPARATOR
Intervention: PIA
Number of subjects: 160
Study 32248934 — intervention group
Group type: EXPERIMENTAL
Intervention: Best possible self or gratitude journal writing intervention (6 weeks, at least 3 entries per week)
Number of subjects: 34
Study 36113576 — intervention group
Group type: EXPERIMENTAL
Intervention: Group prenatal care
Number of subjects: 2350
Study 36113576 — intervention group
Group type: EXPERIMENTAL
Intervention: Group prenatal care (Black participants)
Number of subjects: 2350
Study 36113576 — intervention group
Group type: COMPARATOR
Intervention: Individual prenatal care (Black participants)
Number of subjects: 2350
Study 33188769 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical administration of tranexamic acid
Number of subjects: 90
Study 33188769 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of tranexamic acid
Number of subjects: 90
Study 32026352 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist interventional model (disease education, dietary recommendations, counseling, telephonic follow-up)
Number of subjects: 120
Study 32026352 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist interventional model
Number of subjects: 120
Study 32026352 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 120
Study 32026352 — intervention group
Group type: COMPARATOR
Intervention: Pharmacist interventional model and Control group
Number of subjects: 120
Study 35813842 — intervention group
Group type: EXPERIMENTAL
Intervention: Royal jelly (400 mg) plus coenzyme Q10 (60 mg)
Number of subjects: 20
Study 35813842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 34091663 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets rich in long-chain n-3 fatty acids (LCn3)
Number of subjects: 126
Study 34091663 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets rich in polyphenols (PP)
Number of subjects: 126
Study 34091663 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain cereals (WGC)
Number of subjects: 126
Study 34091663 — intervention group
Group type: COMPARATOR
Intervention: Refined Cereal group
Number of subjects: 126
Study 35500840 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD
Number of subjects: 28
Study 35500840 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 28
Study 35500840 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA
Number of subjects: 28
Study 35500840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 32356212 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser treatment (G1)
Number of subjects: 36
Study 32356212 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery treatment (G2)
Number of subjects: 36
Study 35979802 — intervention group
Group type: EXPERIMENTAL
Intervention: Hughes closure (double far‐near‐near‐far sutures of 1 nylon suture at 2‐cm intervals along the fascia combined with conventional mass closure)
Number of subjects: 802